Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Green Friday! This is a first! $BMSN Go Baby Go!
MAN! HOW DO I KEEP PICKING THESE WINNERS?! $BBDA CALLED IT LAST WEEK!
.0041 x .0043!!!
There, we hit .003 so all the superstitious stories and boogie monsters can shut up now. Go $BMSN!
Folks, nothing "strange" about the trading today imo. People love to exaggerate and then get upset when reality doesn't match their exaggerated expectations. We got good news but it was only about a new hired hand so it shouldn't be expected that we're going to see a 10-bagger today over that. Patience I believe is key here. If you really want to sell that bad then that's your loss imo. You are adults so no one can COMMAND you on what to do. You do what you want to do and you push the buttons based on your gathered information, simple as that. So what, even if we see the 02's today it doesn't change the fact that this is a solid company AIMHO.
Bio-Matrix Scientific Group, Inc. Recruits Senior Scientist for Its Regen BioPharma Subsidiary
SAN DIEGO, CA, Jun 26, 2012 (MARKETWIRE via COMTEX) -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today Thomas E. Ichim, PhD has joined the management team of its Regen BioPharma, Inc. subsidiary as Chief Scientific Officer and Director of Research. Regen BioPharma is the company's translational medicine platform for the rapid commercialization of stem cell therapies.
Dr. Ichim is one of the leading authorities in the world on stem cell biology. To date, he has published 82 peer-reviewed articles and is co-editor of the textbook RNA Interference: From Bench to Clinical Translation. He is also inventor on over 30 patents and patent applications. He currently serves as the CEO of Medistem, Inc., was formerly chief of scientific development, and is the scientific founder / co-founder of Medvax Pharma, ToleroTech, bioRASI, and OncoMune.
David Koos, Chief Executive Officer of Bio-Matrix Scientific Group, stated: "Dr. Ichim is a seasoned biotechnology executive with a track record of scientific excellence. We now have a world-class team to lead our efforts to commercialize stem cell therapies."
About Bio-Matrix Scientific Group, Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group, Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Through its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life. To follow our development, visit us at www.regenbiopharma.com.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.bmsn.us
Email Contact
SOURCE: Bio-Matrix Scientific Group, Inc.
CONTACT: http://www.bmsn.us/
http://www2.marketwire.com/mw/emailprcntct?id=297B144834AF34A1
Copyright 2012 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Trials
You're just figuring that out? LOL..
No one ever claimed the two have a PPS relationship but some folks have a wild imagination.
BMSN is BMSN so stop spamming about that other company.
$BMSN on HIGH ALERT! Eyes are piling up here! Going to head to the beach! This is the easiest money you will ever make. So obvious imo.
Moving on to the next hot play guys, best of luck! I wasn't aware of this foreclosure. I'm up over 125% and that's good enough for me! Thanks for the heads up bud! Looks like it's tanking from here anyway imo.
$HLNT
$BMSN Secures $20,000,000 in Institutional Funding
Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 in Institutional Funding
Southridge Partners to Provide $20 Million in Funding for the Rapid Commercialization of Stem Cell Therapies
SAN DIEGO, CA--(Marketwire - Apr 30, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today it has formed a new subsidiary, Regen BioPharma, Inc. Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.
To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."
The Company also announced that it has secured $20,000,000 in financing from Southridge Partners II, LP of Ridgefield, Connecticut.
This agreement grants the Company the option to sell and obligates Southridge to purchase up to $20,000,000 of common stock over its term. The per share price will be determined based on market prices in accordance with an agreed upon formula and the Company is not obligated to draw on the facility.
The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Southridge of any shares issued to it under the agreement. Subject to the effectiveness of the registration statement and the satisfaction of other customary conditions, the Company may draw on the facility from time to time, as and when it determines appropriate, in accordance with the timing and volume provisions set forth in the agreement.
A spokesperson for the Company noted that Its investment banker, Christopher Schufeldt of Capital Path Securities was instrumental in arranging the funding agreement with Southridge Partners II LP.
About Bio-Matrix Scientific Group, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.
Areas of interest to the Company include:
Diabetes
Chronic Obstructive Pulmonary Disease (COPD)
Heart Related illness
Circulatory issues
THIS HAPPENED JUST LAST MONTH AND I'M EXPECTING 10 CENTS WITHIN THE NEXT 2 MONTHS AIMHO!
$ANTS ON FIRE! CALLED THIS WEEKS BACK +150%!!!
Thanks! Regen BioPharma Inc., Secures $20,000,000 in Institutional Funding.. you just CAN'T BEAT THAT WITH A BAT!
Hang tight bud, don't let an opportunity slip out of your hands over the day to day. Don't be fooled by that. Anyone selling down here will not be celebrating with us very soon. They can chase when it's up in the pennies where it will belong.
$BMSN 10 Cents+ in 2 months! Read up!
Regen BioPharma Inc., Secures $20,000,000
Monday, 30 April 2012 14:00
SOURCE: Bio-Matrix Scientific Group Inc.
April 30, 2012 08:30 ET
Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 in Institutional Funding
Southridge Partners to Provide $20 Million in Funding for the Rapid Commercialization of Stem Cell Therapies
SAN DIEGO, CA--(Marketwire - Apr 30, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today it has formed a new subsidiary, Regen BioPharma, Inc. Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.
To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."
The Company also announced that it has secured $20,000,000 in financing from Southridge Partners II, LP of Ridgefield, Connecticut.
This agreement grants the Company the option to sell and obligates Southridge to purchase up to $20,000,000 of common stock over its term. The per share price will be determined based on market prices in accordance with an agreed upon formula and the Company is not obligated to draw on the facility.
The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Southridge of any shares issued to it under the agreement. Subject to the effectiveness of the registration statement and the satisfaction of other customary conditions, the Company may draw on the facility from time to time, as and when it determines appropriate, in accordance with the timing and volume provisions set forth in the agreement.
A spokesperson for the Company noted that Its investment banker, Christopher Schufeldt of Capital Path Securities was instrumental in arranging the funding agreement with Southridge Partners II LP.
About Bio-Matrix Scientific Group, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs.
Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.
Areas of interest to the Company include:
Diabetes
Chronic Obstructive Pulmonary Disease (COPD)
Heart Related illness
Circulatory issues
Source: http://www.bmsn.us/index.php?option=com_content&view=article&id=59:bio-matrix-scientific-group-inc-announces-newly-formed-stem-cell-subsidiary-regen-biopharma-inc-secures-20000000-in-institutional-funding&catid=35:press-releases&Itemid=63
Haha, no one's giving them shares. TRY AGAIN MM'S!!!
Just MM games, they want cheaper shares.
Good morning to you too sir ! I tip my hat. $BMSN another week here, another dollar! I believe we will reach 10 cents here by Summer time $_$ Go BMSN GO GO GO!!!
$NEOM 10-BAGGER COMING! PAY MY BILLS DR. SOON!
Check out $BMSN if you're looking to make your money back. Much safer play than GWBU and highly predictable. Runs on Monday-Wednesdays and sells off on Fridays. Easy 2-3 baggers to help some of you guys out who got suckered here by Eric V. Nguyen aka APS.
Thanks for the info bro. I've always enjoyed your commentary. Hope you're having a good weekend bud! Cheers!
Nice one Eric V. Nguyen! Done scamming $GWBU homie???? One of these days law enforcement is going to catch up to you and you'll be locked up forever.
Get all the $NEOM you can this thing is going to hit new highs!!!
Dr. Stock Boom Soon IMO! TOLD YOU SO!!! $NEOM
Love how BMSN's a predictable & stable investment. Been making good money here buying early in the week and selling on Thursday/Fridays !
Another great week at BMSN! Run time on Monday!
Wow Rich thanks for that L2! I would've been a fool to sell! Looks like this Friday might be a good one.
I agree!
$BMSN Woo! 1.5 million on bid.. SHORT SQUEEZE ?
Looks like we're headed UP! Perfect time to get in. All technical indicators are pointing up & it looks like the fire has been lit!
Massive dilution here, they've been dumping shares HEAVILY.
Stay away from here.
All IMHO
ICPA seeing RED. I Will be shorting this.
all imho
That was me I just bought 100,500 shares on the ask as soon as I saw that bid, you have to believe it to buy it and I'm buying! Gonna be smacking the ask hard for the rest of the day and the rest will follow. All technical indicators are pointing up!
BOUNCE TIME NO QUESTIONS ASKED. 6MIL ON BID!!
$ATRNQ to the MOOOOOOOOOON!!!! Looking like a WINNER!!!
"We" are down? I didn't know you had access to everyone's personal accounts LOL. Stocks go up and down all the time. This is the part where it goes up. Maybe 1 or 2 people held from 33 cents and if so who cares.. let them keep holding forever. What "we" are talking about is where the stock is going FROM THIS MOMENT RIGHT NOW. Anyone can throw in $1,000 AIMHO today and have 10 grand by Friday (or more as per a lovely woman's opinion here )
The only reason this is under .02 right now IMO is because someone's got a buddy or two that wants to load big tomorrow. How many times am I going to have to say WATCH & LEARN LMAOOOOO?!
Who cares about new shares.. LMAOOOOO.. who's holding this beyond a week or two? Get real pal. This is going to run like a mad woman on steroids and then we put her to rest. IMHO buy now, wait until we hit 10 cents (which it will) and never come back here again... well, until next year LOL. All the boogie man talk you're giving the newbies won't affect my run. Newbies don't have money like that.. it's the old timers that do and they know EXACTLY what's about to happen here.. KAAABOOOM!!!!!!!!!!
Judge can stand on his head and juggle... Has nothing to do with day traders. Long as you can buy and sell this POS before this thing gets shut down it will run right back to 33 cents on speculation alone. You must not know the power of the Q Season.
Watch & learn.. Q Season's begun.. $0.10 Friday you will see. Been doing this for a while and I have learned a thing or two. This is the kick start to the annual Q runs & 70% is peanuts compared to what my account will be by Friday.